A risk-based approach is recommended for analytical method comparability for HPLC assay and impurities methods.
Jeff Hofer
Advertisement
Jeff Hofer is a principal research scientist at Eli Lilly and Company.
Articles by Jeff Hofer
Advertisement
Latest Updated Articles
Analytical Method Comparability in Registration and Post-Approval Stages: A Risk-Based ApproachPublished: October 2nd 2014 | Updated:
Advertisement
Advertisement
Trending on Pharmaceutical Technology
1
Everything to Know About Pharmaceutical Tariffs in 2025
2
New Dosage Forms and Delivery Systems Driving 505(b)(2) Success
3
Behind the Headlines Episode 28: Navigating FDA Shakeups and Obesity Drug Wars
4
Building Resilience in Pharma: Our Top 10 Questions from CPHI Frankfurt
5
